791 related articles for article (PubMed ID: 21847114)
1. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth.
Gaglio D; Metallo CM; Gameiro PA; Hiller K; Danna LS; Balestrieri C; Alberghina L; Stephanopoulos G; Chiaradonna F
Mol Syst Biol; 2011 Aug; 7():523. PubMed ID: 21847114
[TBL] [Abstract][Full Text] [Related]
2. Altered glucose metabolism in Harvey-ras transformed MCF10A cells.
Zheng W; Tayyari F; Gowda GA; Raftery D; McLamore ES; Porterfield DM; Donkin SS; Bequette B; Teegarden D
Mol Carcinog; 2015 Feb; 54(2):111-20. PubMed ID: 24000146
[TBL] [Abstract][Full Text] [Related]
3. Blocking anaplerotic entry of glutamine into the TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs.
Saqcena M; Mukhopadhyay S; Hosny C; Alhamed A; Chatterjee A; Foster DA
Oncogene; 2015 May; 34(20):2672-80. PubMed ID: 25023699
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Melanoma Cell Glutamine Metabolism by Stable Isotope Tracing and Gas Chromatography-Mass Spectrometry.
Scott DA
Methods Mol Biol; 2021; 2265():91-110. PubMed ID: 33704708
[TBL] [Abstract][Full Text] [Related]
5. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis.
DeBerardinis RJ; Mancuso A; Daikhin E; Nissim I; Yudkoff M; Wehrli S; Thompson CB
Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19345-50. PubMed ID: 18032601
[TBL] [Abstract][Full Text] [Related]
6. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling.
Yang C; Sudderth J; Dang T; Bachoo RM; McDonald JG; DeBerardinis RJ
Cancer Res; 2009 Oct; 69(20):7986-93. PubMed ID: 19826036
[TBL] [Abstract][Full Text] [Related]
7. Glutamine deprivation induces abortive s-phase rescued by deoxyribonucleotides in k-ras transformed fibroblasts.
Gaglio D; Soldati C; Vanoni M; Alberghina L; Chiaradonna F
PLoS One; 2009; 4(3):e4715. PubMed ID: 19262748
[TBL] [Abstract][Full Text] [Related]
8. The molecular determinants of de novo nucleotide biosynthesis in cancer cells.
Tong X; Zhao F; Thompson CB
Curr Opin Genet Dev; 2009 Feb; 19(1):32-7. PubMed ID: 19201187
[TBL] [Abstract][Full Text] [Related]
9. Addiction to Coupling of the Warburg Effect with Glutamine Catabolism in Cancer Cells.
Smith B; Schafer XL; Ambeskovic A; Spencer CM; Land H; Munger J
Cell Rep; 2016 Oct; 17(3):821-836. PubMed ID: 27732857
[TBL] [Abstract][Full Text] [Related]
10. Oncogenes and inflammation rewire host energy metabolism in the tumor microenvironment: RAS and NFκB target stromal MCT4.
Martinez-Outschoorn UE; Curry JM; Ko YH; Lin Z; Tuluc M; Cognetti D; Birbe RC; Pribitkin E; Bombonati A; Pestell RG; Howell A; Sotgia F; Lisanti MP
Cell Cycle; 2013 Aug; 12(16):2580-97. PubMed ID: 23860378
[TBL] [Abstract][Full Text] [Related]
11. Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance.
Lim JKM; Delaidelli A; Minaker SW; Zhang HF; Colovic M; Yang H; Negri GL; von Karstedt S; Lockwood WW; Schaffer P; Leprivier G; Sorensen PH
Proc Natl Acad Sci U S A; 2019 May; 116(19):9433-9442. PubMed ID: 31000598
[TBL] [Abstract][Full Text] [Related]
12. Temporal fluxomics reveals oscillations in TCA cycle flux throughout the mammalian cell cycle.
Ahn E; Kumar P; Mukha D; Tzur A; Shlomi T
Mol Syst Biol; 2017 Nov; 13(11):953. PubMed ID: 29109155
[TBL] [Abstract][Full Text] [Related]
13. Parallel labeling experiments with [1,2-(13)C]glucose and [U-(13)C]glutamine provide new insights into CHO cell metabolism.
Ahn WS; Antoniewicz MR
Metab Eng; 2013 Jan; 15():34-47. PubMed ID: 23111062
[TBL] [Abstract][Full Text] [Related]
14. A metabolic core model elucidates how enhanced utilization of glucose and glutamine, with enhanced glutamine-dependent lactate production, promotes cancer cell growth: The WarburQ effect.
Damiani C; Colombo R; Gaglio D; Mastroianni F; Pescini D; Westerhoff HV; Mauri G; Vanoni M; Alberghina L
PLoS Comput Biol; 2017 Sep; 13(9):e1005758. PubMed ID: 28957320
[TBL] [Abstract][Full Text] [Related]
15. 3-BrPA eliminates human bladder cancer cells with highly oncogenic signatures via engagement of specific death programs and perturbation of multiple signaling and metabolic determinants.
Konstantakou EG; Voutsinas GE; Velentzas AD; Basogianni AS; Paronis E; Balafas E; Kostomitsopoulos N; Syrigos KN; Anastasiadou E; Stravopodis DJ
Mol Cancer; 2015 Jul; 14():135. PubMed ID: 26198749
[TBL] [Abstract][Full Text] [Related]
16. Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis.
Daye D; Wellen KE
Semin Cell Dev Biol; 2012 Jun; 23(4):362-9. PubMed ID: 22349059
[TBL] [Abstract][Full Text] [Related]
17. The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism?
Lv J; Wang J; Chang S; Liu M; Pang X
Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):17-26. PubMed ID: 26487443
[TBL] [Abstract][Full Text] [Related]
18. Exo-MFA - A 13C metabolic flux analysis framework to dissect tumor microenvironment-secreted exosome contributions towards cancer cell metabolism.
Achreja A; Zhao H; Yang L; Yun TH; Marini J; Nagrath D
Metab Eng; 2017 Sep; 43(Pt B):156-172. PubMed ID: 28087332
[TBL] [Abstract][Full Text] [Related]
19. The oncogenic transcription factor c-Jun regulates glutaminase expression and sensitizes cells to glutaminase-targeted therapy.
Lukey MJ; Greene KS; Erickson JW; Wilson KF; Cerione RA
Nat Commun; 2016 Apr; 7():11321. PubMed ID: 27089238
[TBL] [Abstract][Full Text] [Related]
20. MTH1 expression is required for effective transformation by oncogenic HRAS.
Giribaldi MG; Munoz A; Halvorsen K; Patel A; Rai P
Oncotarget; 2015 May; 6(13):11519-29. PubMed ID: 25893378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
